The following trials provide information to treat various types of respiratory and inflammatory diseases, both for ongoing and completed clinical trials. For more information on both of these therapy areas please click here.
- collapse A 4 Week Study to Investigate the Safety and Tolerability of AZD5069 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) (CIRRUS)
- collapse AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)
- collapse Japanese single and multiple ascending dose, safety, tolerability, PK & PD study of AZD5069.
- collapse Pharmacokinetics in Adolescents (PEAK)
- collapse The study will evaluate the efficacy of AZD5423 in patients with mild asthma challenged with an inhaled allergen
- collapse A Drug-Drug Interaction Study to Study the Effect of AZD1981 on Warfarin
- collapse Pilot Study of be Fostamatinib Disodium/R935788 for the Treatment of Adult Refractory Immune Thrombocytopenic Purpura (ITP)
- collapse An Open-label, Randomised, No-treatment-controlled, Single-centre, Phase I, Crossover Study Evaluating the Suppression of Plasma Cortisol from Symbicort budesonide/formoterol) pMDI 80/2.25 ?g, 8 Actuations bid, versus Symbicort Turbuhaler 160/4.5 ?g, 4 Inhalations bid, in Healthy Subjects
- collapse A comparative, placebo-controlled, double blind, double dummy, cross-over, single centre, phase IIIb study between formoterol alone (Oxis Turbuhaler 4.5 µg) and the fixed combination of formoterol and budesonide (Symbicort Turbuhaler 160/4.5 µg) on airway responsiveness and airway inflammation induced by repeated low-dose allergen challenge in allergic patients with mild asthma.
- collapse An 8-week, randomised, double blind, parallel-group, multi-centre, phase III study comparing the efficacy and safety of Symbicort Turbuhaler 160/4.5 µg twice daily and Pulmicort Turbuhaler 200 µg twice daily + Theolong tablet 200 mg twice daily in Japanese patients with asthma.
